M. Kmieciak

发表

Phase I study of pemetrexed with sorafenib in advanced solid tumors

John D. Roberts, C. Geyer, P. Dent, 2016, Oncotarget.

IFN-γ Rα Is a Key Determinant of CD8+ T Cell-Mediated Tumor Elimination or Tumor Escape and Relapse in FVB Mouse

M. Manjili, K. Payne, Xiang-Yang Wang, 2013, PloS one.

The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.

S. Grant, A. Berger, L. Povirk, 2016, Blood.

Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas

Derick R. Peterson, J. Friedberg, R. Fisher, 2016, Leukemia & lymphoma.

A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma

John D. Roberts, S. Grant, H. Sankala, 2017, Leukemia & lymphoma.

The role of Tyk2 in regulation of breast cancer growth.

D. Conrad, H. Bear, S. Grant, 2011, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Patients with Melanoma" T Cells in + Self/Tumor Antigen-Specific CD8 despite the Induction of Very High Levels of Comment on "Tumor Progression Can Occur

M. Manjili, J. Keeler, M. Kmieciak, 2012 .

Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2

H. Bear, M. Manjili, M. Kmieciak, 2009, Cancer Immunology, Immunotherapy.

Comment on “Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma”

M. Manjili, J. Keeler, M. Kmieciak, 2006, The Journal of Immunology.

Danger signals and nonself entity of tumor antigen are both required for eliciting effective immune responses against HER-2/neu positive mammary carcinoma: implications for vaccine design

M. Manjili, M. Grimes, M. Kmieciak, 2008, Cancer Immunology, Immunotherapy.

Randomized study of doxorubicin-based chemotherapy regimens, with and without sildenafil, with analysis of intermediate cardiac markers

M. Kontos, R. Kukreja, A. Poklepovic, 2018, Cardio-Oncology.

Chemical Therapeutics The Novel Chk 1 Inhibitor MK-8776 Sensitizes Human Leukemia Cells to HDAC Inhibitors by Targeting the Intra-S Checkpoint and DNA Replication and Repair

S. Grant, Yun Dai, Hui Lin, 2013 .

multiple myeloma through a novel link between autophagy and apoptosis A Bim-targeting strategy overcomes adaptive bortezomib-resistance in

S. Grant, Richard J. Jones, R. Orlowski, 2014 .

Distinct signatures of the immune responses in low risk versus high risk neuroblastoma

F. Marincola, E. Wang, M. Manjili, 2011, Journal of Translational Medicine.

The Role of Myeloid-Derived Suppressor Cells in the Immunotherapy of HER2/neu-Positive Breast Carcinomas

M. Manjili, M. Kmieciak, J. K. Morales, 2009 .

Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells

H. Bear, M. Manjili, M. Feldmesser, 2009, Cancer Immunology, Immunotherapy.

Cloning and characterization of Arabidopsis thaliana AtNAP57--a homologue of yeast pseudouridine synthase Cbf5p.

Z. Szweykowska-Kulinska, M. Kmieciak, J. Maceluch, 2001, Acta biochimica Polonica.

Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells.

S. Grant, J. Leverson, M. Rahmani, 2018, Cancer research.

The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells In Vitro and In Vivo

S. Grant, Liang Zhou, M. Kmieciak, 2019, Clinical Cancer Research.

Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms

John D. Roberts, D. Coppola, S. Grant, 2014, Clinical Cancer Research.

Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis - One Year Update

John D. Roberts, G. Garcia-Manero, S. Grant, 2011 .

Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen‐specific cellular immunity

R. Sabo, M. Manjili, J. McCarty, 2012, British journal of haematology.

Ex vivo expansion of tumor-reactive T cells by means of bryostatin 1/ionomycin and the common gamma chain cytokines formulation.

H. Bear, M. Manjili, A. Toor, 2011, Journal of visualized experiments : JoVE.

Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma: Updated Results

John D. Roberts, S. Grant, H. Sankala, 2014 .

Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function

F. Marincola, H. Bear, M. Manjili, 2009, Journal of Translational Medicine.

Distinct Oligoclonal T Cells Are Associated With Graft Versus Host Disease After Stem-Cell Transplantation

R. Sabo, M. Manjili, J. McCarty, 2012, Transplantation.

A signature of immune function genes associated with recurrence-free survival in breast cancer patients

F. Marincola, H. Bear, E. Wang, 2012, Breast Cancer Research and Treatment.

A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis.

Yun Dai, Hui Lin, Yu Zhang, 2014, Blood.

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma

John D. Roberts, M. Raffeld, Hui-Yi Lin, 2015, Clinical Cancer Research.

A Phase II Trial of AZD 6244 ( Selumetinib , ARRY-142886 ) , an Oral MEK 1 / 2 Inhibitor , in Relapsed / Refractory Multiple Myeloma

John D. Roberts, M. Raffeld, Hui-Yi Lin, 2015 .

Cloning and characterization of two subunits of Arabidopsis thaliana nuclear cap-binding complex.

Artur Jarmolowski, John W. S. Brown, C. Simpson, 2002, Gene.

Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo

S. Grant, R. Orlowski, J. Leverson, 2017, British Journal of Cancer.

Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms

S. Grant, M. Kmieciak, Elisa Hawkins, 2018, BMC Cancer.

Tumor immunoediting and immunosculpting pathways to cancer progression.

M. Manjili, K. Knutson, Jennifer M Reiman, 2007, Seminars in cancer biology.

GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells

H. Bear, M. Manjili, K. Knutson, 2010, Breast Cancer Research and Treatment.

Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.

S. Grant, Hui Lin, Haeseong Park, 2015, Leukemia research.

The Novel Chk1 Inhibitor MK-8776 Sensitizes Human Leukemia Cells to HDAC Inhibitors by Targeting the Intra-S Checkpoint and DNA Replication and Repair

Yun Dai, Hui Lin, S. Grant, 2013, Molecular Cancer Therapeutics.

A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2

John D. Roberts, G. Shapiro, S. Grant, 2013, Clinical Cancer Research.

Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome

Elizabeth B. Collins, John D. Roberts, S. Dave, 2020, Leukemia & lymphoma.

A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations

S. Grant, Yun Dai, C. Dumur, 2014, Leukemia.

Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma

John D. Roberts, P. Dent, R. Sterling, 2019, American journal of clinical oncology.

A phase 1 study of neoadjuvant chemotherapy followed by concurrent chemoradiation with gemcitabine, sorafenib, and vorinostat in pancreatic cancer.

P. Dent, K. Matin, E. Fields, 2021 .

CD4+ T cells inhibit the neu-specific CD8+ T-cell exhaustion during the priming phase of immune responses against breast cancer

F. Marincola, E. Wang, S. Holt, 2011, Breast Cancer Research and Treatment.

Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors.

F. Marincola, H. Bear, E. Wang, 2008, Cancer research.

The Arabidopsis CBP20 targets the cap-binding complex to the nucleus, and is stabilized by CBP80.

P. Wojtaszek, P. Piontek, M. Kmieciak, 2009, The Plant journal : for cell and molecular biology.

Activated NKT Cells and NK Cells Render T Cells Resistant to Myeloid-Derived Suppressor Cells and Result in an Effective Adoptive Cellular Therapy against Breast Cancer in the FVBN202 Transgenic Mouse

Lisa L. Smith, H. Bear, A. Yacoub, 2011, The Journal of Immunology.

HER‐2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell‐mediated anti‐tumor immune responses

M. Manjili, C. Dumur, K. Knutson, 2007, European journal of immunology.

CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.

M. Manjili, C. Dumur, M. Grimes, 2012, Human pathology.

The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo

S. Grant, Yun Dai, Lora B. Kramer, 2019, Journal of Hematology & Oncology.

Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms

S. Grant, M. Rahmani, B. Holkova, 2017, Oncotarget.

abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome ☆

M. Manjili, C. Dumur, M. Grimes, 2012 .

Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce “danger signals”

M. Manjili, K. Knutson, M. Disis, 2006, Breast Cancer Research and Treatment.

Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastasis

H. Bear, M. Manjili, Johanna K. Morales, 2009, Breast Cancer Research and Treatment.

Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation

S. Grant, M. Rahmani, C. Dumur, 2015, Haematologica.

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B‐cell Lymphoma

John D. Roberts, C. Flowers, D. Coppola, 2018, Clinical lymphoma, myeloma & leukemia.

Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure

H. Bear, E. Wang, M. Manjili, 2011, Journal of Translational Medicine.

Non-canonical role for the ataxia-telangiectasia-Rad3 pathway in STAT3 activation in human multiple myeloma cells

S. Grant, Liang Zhou, Xiaoyan Hu, 2023, Cellular Oncology.

LCL161 interacts synergystically with panobinostat in multiple myeloma cells through non-canonical NF-κB- and caspase-8-dependent mechanisms.

S. Grant, Yun Dai, Lora B. Kramer, 2021, Blood advances.

Cancer in the FVBN202 Transgenic Mouse Adoptive Cellular Therapy against Breast Suppressor Cells and Result in an Effective Cells Resistant to Myeloid-Derived Activated NKT Cells and NK Cells Render T

Lisa L. Smith, H. Bear, A. Yacoub, 2011 .

Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies

S. Grant, J. Lancet, M. Rudek, 2023, Cancer Chemotherapy and Pharmacology.

Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms

S. Grant, M. Kmieciak, Elisa Hawkins, 2018, BMC Cancer.

Multi-therapeutic potential of autoantibodies induced by immune complexes trapped on follicular dendritic cells

M. Manjili, C. Pitzalis, J. Tew, 2013, Human vaccines & immunotherapeutics.